This is a standard Form 3 filing for a new insider (CEO). No actionable trading signal — monitor for future Form 4 filings that would indicate open-market purchases or sales.
Price Chart
Executive Summary
Eric Keller, CEO of Retension Pharmaceuticals, filed an initial statement of beneficial ownership (Form 3), disclosing 402,577 shares of common stock, options to buy 241,548 shares, and convertible preferred shares (Series A and B) convertible into 41,030 common shares. This is a routine filing for a new insider and contains no material financial or operational news.
Key Facts
- Eric Keller is CEO of Retension Pharmaceuticals (RTSN).
- Keller directly owns 402,577 shares of common stock.
- Keller holds options to purchase 80,516 shares at $1.43 (expiring 2034-09-22), 128,825 shares at $2.43 (expiring 2035-10-30), and 32,207 shares at $2.43 (expiring 2036-04-30).
- Keller holds Series A Convertible Preferred Stock convertible into 9,662 common shares and Series B Convertible Preferred Stock convertible into 31,368 common shares.
- The filing is an initial ownership report (Form 3) with no transaction or change in holdings.
Financial Impact
No financial impact — this is a routine initial ownership disclosure with no transaction or material event.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-108135 |
| Document: 0001213900-26-108135-index-headers.html | 0001213900-26-108135 |
| Document: 0001213900-26-108135-index.html | 0001213900-26-108135 |
| Document: 0001213900-26-108135.txt | 0001213900-26-108135 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $16.55 | awaiting T+5 | — | $14.55 (−12.11%) |
Oct 16, 2026 9d ago | SC 13G | $16.33 | awaiting T+5 | — | $14.55 (−10.93%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $14.55 (+3.38%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 14, 2026 11d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $14.55 (+19.12%) |
Oct 13, 2026 12d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 13, 2026 12d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $14.55 (+24.96%) |
Oct 9, 2026 16d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $14.55 (+28.49%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
Oct 8, 2026 17d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $14.55 (+38.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers